Howard Safir - Net Worth and Insider Trading

Howard Safir Net Worth

The estimated net worth of Howard Safir is at least $754,495 dollars as of 2024-04-30. Howard Safir is the Director of Verint Systems Inc and owns about 24,693 shares of Verint Systems Inc (VRNT) stock worth over $754,495. Details can be seen in Howard Safir's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Howard Safir has not made any transactions after 2020-12-14 and currently still holds the listed stock(s).

Transaction Summary of Howard Safir

To

Howard Safir Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Howard Safir owns 4 companies in total, including Citius Pharmaceuticals Inc (CTXR) , Verint Systems Inc (VRNT) , and Secure Point Technologies Inc (IMSCQ) among others .

Click here to see the complete history of Howard Safir’s form 4 insider trades.

Insider Ownership Summary of Howard Safir

Ticker Comapny Transaction Date Type of Owner
CTXR Citius Pharmaceuticals Inc 2018-09-04 director
VRNT Verint Systems Inc 2020-12-14 director
IMSCQ Secure Point Technologies Inc 2015-04-16 director
WLKR Walker Innovation Inc 2008-06-26 CEO & SC&I unit

Howard Safir Latest Holdings Summary

Howard Safir currently owns a total of 1 stock. Howard Safir owns 24,693 shares of Verint Systems Inc (VRNT) as of December 14, 2020, with a value of $754,495.

Latest Holdings of Howard Safir

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
VRNT Verint Systems Inc 2020-12-14 24,693 30.56 754,495

Holding Weightings of Howard Safir


Howard Safir Form 4 Trading Tracker

According to the SEC Form 4 filings, Howard Safir has made a total of 1 transactions in Verint Systems Inc (VRNT) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Verint Systems Inc is the sale of 8,333 shares on December 14, 2020, which brought Howard Safir around $501,730.

Insider Trading History of Howard Safir

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Howard Safir Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Howard Safir Ownership Network

Ownership Network List of Howard Safir

No Data

Ownership Network Relation of Howard Safir


Howard Safir Owned Company Details

What does Citius Pharmaceuticals Inc do?

Who are the key executives at Citius Pharmaceuticals Inc?

Howard Safir is the director of Citius Pharmaceuticals Inc. Other key executives at Citius Pharmaceuticals Inc include director & Vice Chairman Myron Z Holubiak , director & 10 percent owner & Chief Executive Officer Leonard L Mazur , and Chief Financial Officer Jaime Bartushak .

Citius Pharmaceuticals Inc (CTXR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Citius Pharmaceuticals Inc (CTXR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Citius Pharmaceuticals Inc (CTXR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Citius Pharmaceuticals Inc (CTXR)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Citius Pharmaceuticals Inc Insider Transactions

No Available Data

Howard Safir Mailing Address

Above is the net worth, insider trading, and ownership report for Howard Safir. You might contact Howard Safir via mailing address: 11 Commerce Drive, First Floor, Cranford Nj 07016.

Discussions on Howard Safir

No discussions yet.